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Abstract 
Wiskott-Aldrich syndrome (WAS) is one of the primary immunodeficiency diseases, that is inherited as an X-linked recessive trait. 
Since the responsible gene, the WASP gene, has been identified, various mutations for patients with WAS have been reported. We found 
a novel splice-site mutation in a patient with clinically diagnosed WAS. The mutation was a replacement ofag by aa in an acceptor site of 
intron 2 of the WASP gene. Sequencing studies of the WASP cDNA of the patient revealed that exon 3 of the WASP gene was 
abnormally missing due to a splicing defect. 
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Wiskott-Aldrich syndrome (WAS) is one of the primary 
immunodeficiency diseases that is inherited as an X-linked 
recessive trait. The disease is characterized clinically by a 
triad of small sized thrombocytopenia, recurrent infections 
due to defects in the immune system, and severe eczema 
[1]. Recently, a responsible gene has been identified and 
named as the Wiskott-Aldrich protein (WASP) gene that 
also has been found to be a responsible gene for X-linked 
thrombocytopenia (XLT) [2,3]. Since then, various muta- 
tions have been reported in patients with WAS or XLT [4]. 
Here we present a novel splice-site mutation in a 6-month- 
old Bangladeshi boy who was clinically suspected to have 
WAS. 
He is the second son of a healthy Bangladeshi couple. 
He had episodes of bloody stool from his first week after 
birth. Petechial and purpuric cutaneous rash were noted in 
his skin. It was found that the number of thrombocytes in
his peripheral blood had decreased to 2.7-9 × 104/mm 3
and his platelet size was also abnormally small (5.6 fl; 
normal range: 7.8-11). His hemoglobin level was 8.0 
gm/dl .  His WBC count was within the normal value 
(7000/ram 3) with mild eosinophilia (850/mm3). He had 
frequent febrile episodes due to bacterial infections, how- 
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ever, he did not have eczema in the skin. His serum 
immunoglobulin level at 6 month old was IgG; 1.51 g/ l ,  
IgA; 0.56 g/ l ,  IgM; 2.4 g/1. 
His elder brother died from intraventricular hemorrhage 
at 2 year old under the condition of persistent thrombocy- 
topenia. He also suffered from frequent bacterial infec- 
tions. A temporal diagnosis of idiopathic thrombocytopecic 
purpura (ITP) was made, however, the results of his bone 
marrow examination were not consistent with ITP. 
Since the patient and the patient's elder brother had 
similar clinical episodes, an X-linked inheritance disease, 
WAS was suspected. 
To make a definite diagnosis for WAS, the patient's 
genomic DNA was purified from his peripheral mononu- 
clear cells, and then a mutation analysis on the WASP 
gene was performed as previously reported [5]. Briefly, we 
amplified 10 fragments, in which 12 exons of the WASP 
gene were included, by PCR and then each fragment was 
directly sequenced. To amplify the fragments including 
each exon of the WASP gene, 0.3-1.0 /zg of DNA was 
PCR amplified in 20 /xl volume using a buffer consisting 
of 50 mM KC1, 10 mM Tris-HC1 pH8.0, 200 mM of 
dNTPs, 100 pM of exon specific each pair of primers and 
2.5 U of Amplitaq ® Polymerase (Perkin-Elmer, Foster 
City, CA). The PCR primers used and conditions for the 
reaction were described in the previous report [5]. The 
amplified fragments were purified and then, were directly 
sequenced by using an ABI PRISM TM Dye Terminator 
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Cycle Seaquencing Ready Reaction Kit (Perkin Elmer, 
Foster City, CA) and an automated ABI 373A DNA 
sequencer. Primers used for sequencing were the same as 
those used for PCR at a concentration of 3.2 pM. The 
detected mutation was reconfirmed using different sets of 
PCR product. 
There was no abnormalities in the entire cording region 
of the WASP gene of the patient, however, a one base 
replacement of ag by aa in an acceptor site of intron 2 was 
found (Fig. 1). Since a change of this site seemed to 
induce a splicing abnormality, we studied the patient's 
WASP cDNA by RT-PCR as previously reported [6]. RNA 
was purified from the patient's peripheral mononuclear 
cells using RNA isolation solvent (RNAzol TM Cinna/Bio- 
tecx, Houston, TX), and then the cDNA was synthesized 
using a first strand cDNA synthesis kit (Pharmacia LKB 
Biotechnology, Uppsala, Sweden). A part of the cDNA 
from the WASP gene was amplified by PCR. Primers used 
were a sense primer corresponding to exon 2 
(ACTGCAGTTGTTCAGCTGTA) and an antisense primer 
corresponding toexon 4 (CCACTTTGCCTCTGATTCCT). 
The conditions for PCR were denaturation at 94°C for 30 
s, annealing at 60°C for 30 sec and polymerization at 72°C 
for 30 s. Twenty-five cycles of amplification were per- 
formed. As expected, the fragment from the patient was 
abnormally smaller than that of the healthy control (data 
not shown). The patient's fragment appeared to be approx- 
imately 230 bp in length, whereas 320 bp of the fragment, 
exactly the same as the expected size, was detected from 
the control. No other extra band was observed in either the 
patient or the control. This size difference between the 
patient's fragment and the control's fragment was the same 
as the size of exon 3. Finally, sequencing studies of both 
the fragments revealed that sequences corresponding to 
exon 3 of the WASP gene were missing from the patient's 
fragment (Fig. 1). Although other mutations in the WASP 
gene that would result in a splicing defect have been 
reported [7-9], this is a novel splice-site mutation for a 
WAS patient. It was shown that intron 2, exon 3, and 
intron 3 were spliced out from the patient's mRNA of the 
WASP gene. Although a new acceptor site (ag) was cre- 
ated by agg to aag base change (italics; using the first 
nucleotide of exon 3), it was shown that this site did not 
work as a functional acceptor site. Furthermore, it also was 
indicated that there was no cryptic acceptor site in intron 2, 
exon 3 and intron 3. 
Although the function of the WASP gene product has 
not been well studied, its binding to Nck [10] and CDC42Hs 
[11] has recently been indicated. Furthermore, two con- 
served motifs named WASP homology 1 and 2 (WH1, 
WH2) has been proposed as functional domains [11]. The 
portion corresponding to exon 3 includes a part of the 
WH1 domain. The skipping out of exon 3 would not create 
a frame shift change, and we could detect an abnormal 
Genome sequence cDNA sequence 
control 
pati ent 
I 
CTACACCTCTCCAGGCTGGTCGGCTGC 
i ntron 2 exon 3 
CTACACCTCTCCAAGCTGGTCGGCTGC 
t 
r-FACGGCCI-FCAC.- GGTCGGC 
exon 2 exon 3 
exon 2 exon 4 
TTACGC CVI-CAGGACTGCCAAG 
Fig. 1. Genomic and cDNA sequence ofthe WASP gene from the patient with WAS. Left two columns indicate results of genomic sequence ofthe WASP 
gene and right two columns indicate cDNA sequence ofthe WASP gene. Difference between the patient and the control individual is shown as underlined 
or arrows. Vertical dotted lines are borders of intron/exon or exon/exon. 
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transcript of the WASP gene by RT-PCR. Thus, in the 
case where a defective WASP is produced in a high 
enough level in the patient's cells, the defect of this 
domain of the WASP may be responsible for the patient's 
clinical phenotype. We are now planning to study the 
WASP of patients with WAS by Western blot analysis. 
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